The threat and prospects for control of an influenza pandemic

Expert Review of Vaccines

Volumn 3, Issue 1, 2004, Pages 35-42

  Stiver, H Grant ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiviral drugs; Influenza epidemiology; New future influenza vaccines; Pandemic influenza

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; DNA VACCINE; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PROTEASOME; PROTEIN M2; RIMANTADINE; SIALIDASE; ZANAMIVIR;

ANTIGENIC SHIFT; ANTIGENIC VARIATION; EPIDEMIC; HEALTH CARE COST; HONG KONG; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURAL GENE; UNITED STATES; VACCINE PRODUCTION; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED; VACCINES, DNA; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 1042268187     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.1.35     Document Type: Review

References (46)

1. Cox NJ, Subbarao K. Global epidemiology of influenza. Ann. Rev. Med 51, 407-421 (2000). Reviews the importance of the worldwide epidemiology of influenza and its impact on world health.
2. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20, 3068-3087 (2002).
3. Stiver HG, Graves P, Eickhoff TC, Meiklejohn G. Efficacy of 'Hong Kong' vaccne in preventing 'England' variant influenza A in 1972. N. Engl J. Med. 289, 3-7 (1973).
4. Read CA, Mohsen A, Nguyen-Van-Tam JS et al. Outbreaks of influenza A in nursing homes in Sheffield during the 1997-1998 season; implications for diagnosis and control. J. Public Health Med. 22, 116-120 (2000).
5. Potter C. Chronicle of influenza pandemics In: Textbook of Influenza, Nicholson KG, Webster RG, Hay AJ (Eds.), Blackwell Science, London, UK 3-18 (1998).
6. Oxford J. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev. Med. Virol. 10, 119-133 (2000).
7. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Ann. Rev. Med. 51, 407-421 (2000).
8. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20, 3068-3087 (2002).
9. Henderson DA. Pandemic preparedness: lessons from the past. Antiviral Res. 50, 157-196 (2001).
10. Kendal AP, Noble GR, Skehell J, Dowdle WR. Antigenic similarity of influenza (H1N1) viruses from epidemics in 1977-1978 to 'scandinavian' strains isolated in epidemics of 1950-1951. Virology 89, 632-636 (1978).
11. Luc J, Gross P, Thompson W. Observations on mortality during the 1918 influenza pandemic. Clin. Infect. Dis. 33, 1375-1378 (2001). Data in this paper suggest that the 1918 Spanish flu virus subtype may have circulated in humans 75 years or more before 1918.
12. Dowdle WR, Coleman MT, Gregg MB. Natural history of influenza type A in the United States, 1957-1972. Prog. Med. Virol. 17, 91-135 (1974).
13. Fine M, Auble T, Yeale D et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243-250 (1997).
14. Taubenberger JK, Reid AH, Janczewski TA, Fanning TG. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 1829-1839 (2001). Contains novel research data on the genetic composition of the 1918 pandemic influenza virus obtained from PCR studies of tissues from a person who died in the arctic and whose body was preserved in a permafrost grave in Brevig Mission, Alaska.
15. Zambon MC. The pathogenesis of influenza in humans. Rev. Med. Virol. 11, 227-241 (2001).
16. Basler CF, Reid AH, Dybing JK et al. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc. Natl. Acad. Sci. USA 98, 2746-2751 (2001).
17. Snacken R, Kendal AP, Haaheim LR, Wood JM. The next influenza pandemic: lessons from Hong Kong, 1997. Emerg. Infect. Dis. 5, 195-203 (1999). Emphasizes important steps to be implemented in case of an impending pandemic using the Hong Kong H5N1 avian influenza outbreak of 1997 as an example.
18. Patriarca PA, Cox NJ. Influenza preparedness plan for the United States. J. Infect. Dis. 176(Suppl. 1), S4-S7 (1997). Outlines the pandemic preparedness plan of the influenza center for the Americas.
19. van Genugten MLL, Heijnen M-LA, Jager, JC. Pandemic influenza and healthcare in the Netherlands: scenario analysis. Emerg. Infect. Dis. 9, 531-538 (2003). Describes a model for decision-making and cost-benefit analysis for interventions to manage an influenza pandemic in the Netherlands.
20. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998). Describes the excellent protective efficacy and safety of a new live cold-adapted attenuated intranasal influenza vaccine in children, and its protective effect against an antigenically drifted influenza variant.
21. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr. Infect. Dis. 19(Suppl. 5), S66-S71 (2000). These data demonstrate that the live cold-adapted intranasal influenza vaccine can reduce the incidence of otitis media in children and decrease use of antibiotics as a consequence.
22. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136, 139-141 (2000).
23. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117, 625-633 (1992).
24. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children J. Infect. Dis. 122, 16-24 (1970). This important paper shows that influenza vaccination of school children reduces the infection rate in the general population and supports the notion that the pool of school children act as a source for disseminating influenza into the adult population where higher risk groups exist.
25. Poland GA, Breese Hall C. Influenza immunization of schoolchildren: can we interrupt community epidemics? Pediatrics 103, 1280-1282 (1999).
26. Palache GC, Wood JM, Newman RW. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells of fertilized chicken eggs. 176(Suppl. 1), S20-S23 (1997). These data show that using MDCK tissue culture techniques for production of influenza vaccine virus allows production of an immunogenic, safe vaccine with the potential of circumventing the time-consuming egg-adaptation problems associated with current commercially available vaccines.
27. Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosomal influenza vaccines induces serum HAI, mucosal IgA and protections against influenza challenge. Vaccine 20, 218-225 (2001).
28. Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305, 192-200 (2003). H5N1 virulent avian influenza virus is toxic to hens' eggs making vaccine production in eggs problematic. The techniques of reverse genetics can be used to engineer vaccine virus with the desired immunogenic characteristics while omitting the egg-toxic characteristics.
29. Ulmer JB, Donnely JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993). The first paper demonstrating that immunization with DNA encoding a type-specific nucleoprotein antigen from an A H1N1 influenza virus, protected animals challenged with a heterosubtypic A H3N2 virus, supporting the idea that DNA vaccination research could potentially lead to a universal influenza vaccine.
30. Neirynck S, Deroo T Saelens X et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157-1120 (1999).
31. Okuda K, Ihata A, Watabe S et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza A gene. Vaccine 19, 3681-3691 (2001).
32. Webster RG. DNA vaccination: a potential future strategy. In: Textbook of Influenza. Nicholson Kg, Webster RG, Hay AJ. (Eds.). Blackwell Science, London, UK. 410-421 (1998).
33. Stiver HG. The treatment of influenza with antiviral drugs. Can. Med. Assoc. J. 168, 49-56 (2003).
34. Hayden FG Sperber SJ, Belshe RB et al. Recovery of drug-resistant influenza A during therapeutic use of rimantadine. Antimicrob. Agents Chemother. 35, 1741-1747 (1991). Shows that rimantadine treatment of an index case of influenza is associated with emergence of rimantadine-resistant influenza virus that can be infectious for family contacts. Thus widespread use of an ion channel blocker may have limitations in a pandemic.
35. Bowles SK, Lee W, Seymor AE et al. Use of oseltamivir during outbreaks in Ontario nursing homes, 1999-2000. Am. J. Getriatr. Soc. 50, 608-616 (2002).
36. Monto AS, Fleming DM, Henry D et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B infections. J. Infect. Dis. 180, 254-261 (1999). Provide data from double-blind randomized trials showing the benefit of the neuraminidase inhibitor zanamivir in treating influenza. The use of these agents is not associated with significant rates of viral resistance and they would be of great value in an influenza pandemic.
37. MIST study group. Randomized trial of efficacy and safety of inhaled zanamivir in the treatment of influenza A and B infections. Lancet 352, 1877-1881 (1998).
38. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 355, 1845-1850 (2000). Provide data from double-blind randomized trials showing the benefit of the neuraminidase inhibitor oseltamivir in treating influenza. The use of these agents is not associated with significant rates of viral resistance and they would be of great value in an influenza pandemic.
39. Aoki FY, Mcleod MD, Paggiaro P et al. Early administration of oral oseltamivir maximizes the benetits of influenza treatment. J. Antimicrob. Chemother. 51, 123-129 (2003). Provide data from double-blind randomized trials showing the benefit of the neuraminidase inhibitor oseltamivir in treating influenza.
40. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A H1N1 neuraminidase active site following oseltamivir phosphate tratment leaves virus severely compromized both in vitro and in vivo. Antiviral Res. 55, 307-317 (2002).
41. Jefferson T, Demicheli V. Socioeconomics of influenza. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds.). Blackwell Science, London, UK 541-547 (1998).
42. Meunnig PA, Khan K. Cost effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 33, 1879-1885 (2001).
43. Kavet J. A perspective on the significance of pandemic influenza. Am. J. Publ. Health. 66, 1063-1070 (1977).
44. Banzhoff A, Nacci P, Podda A. A new MF-59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49, 177-184 (2003).
45. Liposomal influenza vaccine. Biodrugs 11, 137-146 (1999).
46. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 362, 1733-1745 (2003).